Today: 3 July 2026
Browse Category

NASDAQ:ABVX 20 November 2025 - 30 June 2026

Abivax (NASDAQ:ABVX) ADS gain $2.3B after obefazimod safety news; Paris session yet to start

Abivax (NASDAQ:ABVX) ADS gain $2.3B after obefazimod safety news; Paris session yet to start

Abivax S.A. is set for a lagged Paris opening after its U.S. ADS jumped in after-hours trading. Investors reacted to new clinical data on obefazimod, Abivax’s ulcerative colitis drug. The latest news hits late, but the drop earlier this month wasn’t about whether the drug works. It was about the potential cancer risk and what that could mean for the drug’s label. Abivax put out the release at 22:05 CEST, after Euronext Paris had already closed for the day at 17:30 and just past the U.S. market close. Euronext Paris trades from 9:00 a.m. to 5:30 p.m. local time and, according to its 2026 holiday calendar, June 30 isn’t a holiday.
30 June 2026
···
Abivax Stock Sees Big After-Hours Moves After Trial Result

Abivax Stock Sees Big After-Hours Moves After Trial Result

Abivax shares tumbled in late U.S. trading on Monday, despite the French biotech putting out positive late-stage results for its main ulcerative colitis drug. The American depositary shares were at $86.01 after hours, a drop of 33.7% from their regular close at $129.69, according to Google Finance. Abivax cleared a key clinical hurdle with the results, setting up for a planned U.S. submission. Phase 3 is the last big step in trials before regulators rule on drug approval, usually the final check before sales can begin.
2 June 2026
···
Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

Abivax (ABVX) Stock in Focus: Eli Lilly Takeover Chatter, Obefazimod Phase 3 Momentum, and What to Watch Before the Next U.S. Session

NEW YORK — Friday, December 26, 2025: U.S. stocks are heading into a thin, post‑Christmas trading day, with Wall Street set for a relatively muted open as investors digest a strong 2025 tape and look ahead to 2026 rate and earnings narratives. Reuters In that kind of tape, headline-driven biotech names can swing harder than usual—and ABIVAX Société Anonyme has been exactly that kind of stock in December: a mix of clinical-trial enthusiasm, index-related positioning, and renewed takeover speculation.
26 December 2025
···
ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

ABIVAX (ABVX) Stock Surges on Eli Lilly Takeover Talk as Nasdaq Biotech Index Inclusion Kicks In — News, Forecasts and Outlook (Dec. 22, 2025)

December 22, 2025 — ABIVAX Société Anonyme is back in the spotlight today, with traders juggling two storylines that can move a biotech stock fast: renewed takeover speculation involving Eli Lilly and Abivax’s addition to the Nasdaq Biotechnology Index, effective before today’s market open. GlobeNewswire+2Investing.com+2 In early market action, multiple outlets reported double‑digit gains in Abivax’s U.S. premarket trading and strong moves in Paris, making ABVX one of the morning’s most-watched biotech tickers. Benzinga+2Investing.com+2
22 December 2025
····
ABIVAX Société Anonyme (ABVX) Stock News on Dec. 16, 2025: Shares Slide After Q3 Loss Widens, While Analysts Keep Buy Calls and M&A Talk Lingers

ABIVAX Société Anonyme (ABVX) Stock News on Dec. 16, 2025: Shares Slide After Q3 Loss Widens, While Analysts Keep Buy Calls and M&A Talk Lingers

December 16, 2025 — ABIVAX Société Anonyme is back in the spotlight today after publishing third-quarter 2025 financial results and reiterating a long cash runway—news that didn’t stop the stock from pulling back as investors digested widening losses and the sheer scale of the rally already priced in. In U.S. trading, Abivax’s Nasdaq-listed shares were down about 5% around mid-session, at roughly $111–$112. StockAnalysis In Paris, Abivax shares were also lower earlier in the day, with one market report citing a drop of about 5.7% during the European morning. Investing.com South Africa
16 December 2025
···
Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax (ABVX) Stock Jumps on Eli Lilly Takeover Rumors: Latest News, Outlook and Forecasts – December 10, 2025

Abivax Société Anonyme is back in the spotlight on December 10, 2025, after its share price spiked again on fresh takeover speculation involving U.S. pharma giant Eli Lilly. The move caps an extraordinary year in which the French biotech has transformed from a relatively obscure name into a multibillion‑euro inflammatory bowel disease contender.Reuters+1 Below is a detailed rundown of today’s news, the fundamental drivers, and the latest forecasts and analyses being published about Abivax.
10 December 2025
····
Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax (ABVX) Stock Jumps on AstraZeneca Takeover Rumors: Outlook for November 20, 2025

Abivax SA, the French biotech behind the inflammatory bowel disease drug candidate obefazimod, is back on traders’ screens today as the stock spikes on fresh takeover chatter involving pharma giant AstraZeneca. As of mid‑afternoon U.S. trading on Thursday, November 20, 2025, ABVX stock is trading around $121.94, up roughly 8% from Wednesday’s close of $112.95. Intraday, shares have ranged between about $113.63 and $126.42, on heavy volume of roughly 3.7 million American Depositary Shares. Stock Invest
20 November 2025
··

Stock Market Today

  • Genuine Parts Jumps After O’Reilly’s $10 Billion Auto Unit Offer
    July 3, 2026, 11:07 AM EDT. Genuine Parts Company (NYSE:GPC) shares shot up 12.9% to $132.57 after O'Reilly Automotive (NASDAQ:ORLY) was reported to have made a cash bid for GPC's auto parts business, tacking on about $2.1 billion to GPC's market cap. The offer puts the auto unit at a $10 billion value, or 8.3 times expected 2025 EBITDA. That leaves GPC's Motion industrial parts arm at an implied $8.2 billion. Investors are trying to figure out if management goes for the deal, spins off the unit, or waits for more offers. Genuine Parts reports Q2 results July 21. O'Reilly shares dropped 2.7% with the market signaling some concern over the potential acquisition's price and strategy.
Go toTop